

THE WALL STREET JOURNAL.

JANUARY 5, 2007

Roche and Synosis Join To Develop Five Drugs

Swiss drug maker Roche Holding AG reached a partnership agreement with Synosis Therapeutics for development of five drugs to treat schizophrenia, cognitive disorders, Parkinson's, drug dependency and pain. Synosis, a closely held U.S. biotechnology company, will acquire five drug candidates from Roche, four in Phase I clinical trials, the companies said. Financial terms weren't disclosed. Synosis, of San Francisco, will be responsible for the drugs' clinical development and, in some cases, their commercialization.

THE WALL STREET JOURNAL.

EUROPE

JANUARY 5, 2007

Swiss drug maker Roche Holding AG reached a partnership agreement

with Synosis Therapeutics for the development of five drugs to treat schizophrenia, cognitive disorders, Parkinson's, drug dependency and pain. Synosis, a closely held U.S. biotechnology company, will acquire five drug candidates from Roche, four of them in Phase I clinical trials, the companies said. Financial terms weren't disclosed. Development had been discontinued by Roche. "This is a more novel way of continuing to extract value from Phase I projects which are no longer priorities for Roche," Dresdner Kleinwort analysts said in a note. Synosis, based in San Francisco, will be responsible for the clinical development and, in some cases, commercialization of the drugs.